The landscape of metabolic dysfunction-associated steatohepatitis (MASH) drug development reached a potentially pivotal turning point in 2025. This was the year that PathAI’s AIM-MASH AI Assist* digital pathology tool achieved landmark regulatory recognition, securing both EMA qualification and FDA Drug Development Tool (DDT) qualification [1,2]. These regulatory milestones have brought the MASH field closer to a new era where integration of AI-powered scoring tools into clinical trials provide the standardized, reproducible scoring necessary for accurate trial enrollment and endpoint assessme